Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 501 - 550 out of 20,262

Document Document Title
WO/2022/002102A1
Provided herein are novel compounds, for example, compounds having a Formula (I), Formula (II), or Formula (III), or a pharmaceutically acceptable salt thereof. Also provided herein are methods of preparing the compounds and methods of u...  
WO/2021/260090A1
The invention relates to compounds of Formula (I) wherein X1, X2, X3, L, RX4, R1, R2A, R2B, R3, R4, R5, and R6 are as described in the description; to their preparation, to pharmaceutically acceptable salts thereof, to pharmaceutical com...  
WO/2021/259815A1
The present invention provides compounds of formula I or II: wherein X1, X3, R1, R2, R3, R4 and R5 are as described herein, as well as pharmaceutically acceptable salts thereof. Further the present invention is concerned with the manufac...  
WO/2021/223650A9
The present application relates to a nitrogen-containing compound. The structural formula of the nitrogen-containing compound is as shown in formula I, in which ring A and ring B are each independently selected from a benzene ring or a f...  
WO/2021/256883A1
The present invention relates to a novel compound and an organic electroluminescent device comprising same. The compound according to the present invention can be used in an organic material layer of an organic electroluminescent device,...  
WO/2021/256881A1
The present invention relates to a novel compound having excellent light-emitting ability and an organic electroluminescent device comprising same, in which the compound according to the present invention is used in organic material laye...  
WO/2021/254464A1
A substituted quinazoline compound, and a preparation method therefor, a pharmaceutical composition thereof, and a use thereof. Specifically, the present invention relates to a substituted quinazoline compound having BRK and/or BTK kinas...  
WO/2021/256871A1
The present invention relates to a novel compound exhibiting excellent light-emitting performance and an organic electroluminescent device comprising same. The compound according to the present invention is used in an organic layer of an...  
WO/2021/254920A1
Provided herein is a process for synthesis of intermediates for ipatasertib related to large scale manufacture of (R)-5-methyl-4-(piperazin-1-yl)-5,6-dihydro-7H-cyclopenta[d] pyrimidin-7-one.  
WO/2021/256880A1
The present invention relates to a novel compound having excellent light-emitting ability and an organic electroluminescent device comprising same. The compound according to the present invention can be used for the material of an organi...  
WO/2021/255429A1
The invention includes a process for the synthesis of N,N-dimethyl-4-((6-oxopyrimidin-1(6H)- yl)methyl)benzamide and 4-((6-oxopyrimidin-1(6H)-yl)methyl)benzoic acid, a process for 5 synthesising crystalline forms of N,N-dimethyl-4-((6-ox...  
WO/2021/255436A1
• A composition comprising 4-((6-oxopyrimidin-1(6H)-yl)methyl) benzoic acid, • 4-((6-oxopyrimidin-1(6H)-yl)methyl) benzoic acid for use as a medicament, • 4-((6-oxopyrimidin-1(6H)-yl)methyl) benzoic acid for use in a method of trea...  
WO/2021/250558A1
The invention provides an improved process for the preparation of fluoxastrobin and intermediates thereof. The present invention provides a process for the preparation of fluoaxastrobin, 4,6-dichloro-5-fluoro-pyrimidine and diethyl 2-chl...  
WO/2021/250521A1
Provided herein is a compound of the Formula I: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7 and L are as defined herein, for the treatment of BRAF-associated diseases and disorders, including BRAF-as...  
WO/2021/252680A1
Disclosed herein are certain 4-arylquinazoline derivatives of Formula (I) that are methionine adenosyltransferase 2A (MAT2A) inhibitors. Also disclosed are pharmaceutical compositions comprising such compounds and methods of treating dis...  
WO/2021/252475A1
Provided herein is a compound of Formula (I): or a pharmaceutically acceptable salt thereof, wherein the variables are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) and methods ...  
WO/2021/247634A1
Provided herein are compounds of Formula (I''), Formula (I'), Formula (I), Formula (II'), and Formula (II), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labele...  
WO/2021/244560A1
Provided herein are novel compounds, for example, compounds having a Formula (I) or Formula (II), or a pharmaceutically acceptable salt thereof. Also provided herein are methods of preparing the compounds and methods of using the compoun...  
WO/2021/244582A1
The present application provides a novel thyroid hormone β receptor agonist having better activity, selectivity or safety and represented by formula (I), and use thereof in preventing or treating a disease related to the β receptor ago...  
WO/2021/247732A1
The present invention relates to compounds of formula I (I) as well as to the compounds of formula I for use as transmembrane serine protease 2 (TMPRSS2) inhibitors in the treatment of viral infections, such as e.g. corona virus infectio...  
WO/2021/246713A1
The present specification relates to a compound of chemical formula 1, and an organic light-emitting device comprising same.  
WO/2021/245087A1
The present disclosure relates to heterocyclyl pyrimidine and heterocyclyl triazine compounds, processes and intermediates for their preparation as well as the uses thereof for controlling phytopathogenic microorganisms, such as phytopat...  
WO/2021/238835A1
The present invention relates to a crystal form C of (2E)-N-[4-[(3-chloro-4-fluorophenyl)amino]-7-methoxy-6-quina zolinyl]-4-(1-piperidinyl)-2-butenamide, and a preparation method therefor and a drug containing same. The crystal form C i...  
WO/2021/238908A1
The present invention relates to a salt and a crystal form containing a heteroaryl derivative. The present invention specifically relates to a salt and a crystal form comprising a compound of general formula (I), a preparation method, an...  
WO/2021/239643A1
The present invention relates to a compounds of general formula (I) inhibiting DDR1 and DDR2, particularly the invention relates to compounds that are benzylamine derivatives, methods of preparing such compounds, pharmaceutical compositi...  
WO/2021/236449A1
Disclosed herein are p38a mitogen-activated protein kinase inhibitors, pharmaceutical compositions thereof, and therapeutic methods of using the p38a mitogen-activated protein kinase inhibitors.  
WO/2021/236775A1
The present disclosure provides compounds represented by Formula I: and the salts or solvates thereof, wherein R1, R3, L, Y, and B1 are as defined in the specification. Compounds having Formula I are SHP2 protein degraders useful for the...  
WO/2021/237004A1
The present disclosure encompasses novel solid state forms of Aprocitentan, Aprocitentan salts and Aprocitentan co-crystals, processes for preparation thereof, and pharmaceutical compositions thereof.  
WO/2021/235283A1
The present invention provides: a radiation sensitive resin composition which is capable of exhibiting sensitivity, CDU performance and LWR performance at sufficient levels; and a method for forming a resist pattern. A radiation sensitiv...  
WO/2021/228945A1
The present invention relates to the use of at least one compound of formula (I), or one of its pharmaceutically acceptable salts, for preventing and/or treating a disease caused by a nonsense mutation. It also relates to compounds of fo...  
WO/2021/231726A1
The disclosure provides compositions and methods of quinoline, quinazolines, and pyrydylpyridines derivatives for the inhibition of ENPP1 modulators.  
WO/2021/226814A1
Disclosed are a small-molecule compound SPAM1 for up-regulating a neuropeptide PACAP and a receptor PAC1-R thereof, and a preparation method therefor and an application thereof. The structure of the SPAM1 is as shown in formula (I), wher...  
WO/2021/228734A1
The present disclosure relates to triazine and pyrimidine (thio)amide compounds, processes and intermediates for their preparation as well as the uses thereof for controlling phytopathogenic microorganisms, such as phytopathogenic fungi.  
WO/2021/224927A1
The invention in some embodiments thereof, relates to the field of compositions and/or pharmaceutical compositions comprising one or more biologically active compound, and is directed to methods of using same such as for treating an ApoL...  
WO/2021/224802A1
The present invention provides a stable, liquid composition comprising: (a) a fungicidally effective amount of a compound of Formula I, and (b) a liquid carrier, wherein: (i) the composition comprises (a) a fungicidally effective and sub...  
WO/2021/226629A1
The present disclosure provides compounds of Formula (I), useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 ("TREM2"). This disclosure also provides pharmaceutical compositions comprising the compounds, uses o...  
WO/2021/226260A1
The present invention provides crystalline forms of (E)-6-(4-Phenylcyclohexyl)-5-(3-trifluoromethylbenzyl)-1H-py rimidine-2,4-dione, and methods of making and using the same.  
WO/2021/226258A1
The present invention provides formulations of (E)-6-(4-Phenylcyclohexyl)-5-(3-trifluoromethylbenzyl)-1H-py rimidine-2,4-dione, and methods of making and using the same.  
WO/2021/225969A1
The present disclosure relates generally to inhibitors of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), compositions thereof, and methods of using said compounds and compositions thereof. More specifically, the present disc...  
WO/2021/225878A1
The present invention provides a compound of Formula (I): wherein R1 is hydrogen or methyl; and R2 is: or a pharmaceutically acceptable salt thereof, useful for treating pain, including chronic pain, chronic lower back pain, diabetic per...  
WO/2021/226161A1
An improved process for preparing verdiperstat is disclosed. The process includes the steps of reacting a compound having formula or a salt thereof, wherein R is the same or different and is each independently a C1-C5 alkyl with 3-(dimet...  
WO/2021/218588A1
The present application belongs to the field of organic light-emitting materials, and specifically relates to a nitrogen-containing compound, an electronic component using same and an electronic device. The nitrogen-containing compound h...  
WO/2021/219513A1
The present application relates to the compounds of formula (I), and the N-oxides, stereoisomers, tautomers and agriculturally or veterinarily acceptable salts thereof wherein the variables are defined in the claims. The compounds of for...  
WO/2021/222888A1
The disclosure provides a rapidly deployable nanoscale biodegradable system using hydroxypropyl beta cyclodextrin based combination product. Cyclodextrin is an amphiphilic polymer suitable to develop an agnostic barrier blocking pathogen...  
WO/2021/219594A1
The invention relates to compounds of Formula (I) wherein X1, X2, X3, Y, R1, R2A, R2B, R3, and R4 are as described in the description; to their preparation, to pharmaceutically acceptable salts thereof, to pharmaceutical compositions con...  
WO/2021/218110A1
A benzothiazolyl biaryl compound represented by general formula I, or a pharmaceutically acceptable salt thereof, or an enantiomer, a diastereoisomer, a tautomer, a torsional isomer, a solvate, a polymorph, or a prodrug thereof, a prepar...  
WO/2021/222365A1
A topical skincare composition that includes (A) a reducing sugar, (B) an aromatic sulfonate having a topological polar surface area (tPSA) of less than 100 Å2, and (C) a carrier. A method for adjusting color appearance (e.g., hue angle...  
WO/2021/216705A1
The present disclosure relates to compounds of Formula (I) that modulate the activity of G-protein coupled receptor 52 (GPR52), pharmaceutically acceptable salts of compounds of Formula (I), and pharmaceutical compositions thereof. Compo...  
WO/2021/213518A1
The present invention relates to the field of biomedicine, and specifically relates to an "LC3 binding portion-lipid droplet binding portion-conjugate" formed by means of covalently linking a structure capable of binding LC3 and a struct...  
WO/2021/216440A1
The present disclosure describes novel protein kinase inhibitors and methods for preparing them. The pharmaceutical compositions comprising such protein kinase inhibitors and methods of using them for treating cancer and other diseases, ...  

Matches 501 - 550 out of 20,262